Anavex Life Sciences Corp. (AVXL) has a negative trailing P/E of -6.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.4 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -14.83%, forward earnings yield 69.93%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 59/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -8.7 | 0.24 | 20.23 | 0.00 | - |
| 2017 | -12.6 | 0.59 | 6.97 | 0.00 | - |
| 2018 | -6.6 | -0.36 | 5.62 | 0.00 | - |
| 2019 | -5.9 | -0.15 | 7.62 | 0.00 | - |
| 2020 | -10.1 | 0.60 | 9.72 | 0.00 | - |
| 2021 | -33.1 | -1.65 | 8.31 | 0.00 | - |
| 2022 | -16.5 | -1.12 | 5.57 | 0.00 | - |
| 2023 | -11.0 | 3.41 | 3.68 | 0.00 | - |
| 2024 | -11.0 | 0.83 | 3.94 | 0.00 | - |
| 2025 | -16.4 | -4.26 | 8.00 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.42 | $0.00 | $-14.74M | - |
| 2017 | $-0.33 | $0.00 | $-13.46M | - |
| 2018 | $-0.39 | $0.00 | $-17.45M | - |
| 2019 | $-0.54 | $-685K | $-26.3M | - |
| 2020 | $-0.45 | $0.00 | $-26.28M | - |
| 2021 | $-0.54 | $0.00 | $-37.91M | - |
| 2022 | $-0.62 | $0.00 | $-47.98M | - |
| 2023 | $-0.60 | $0.00 | $-47.51M | - |
| 2024 | $-0.52 | $0.00 | $-43M | - |
| 2025 | $-0.54 | $0.00 | $-46.38M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.33 | $-0.33 – $-0.33 | $776M | $776M – $776M | 1 |
| 2027 | $-0.14 | $-0.14 – $-0.14 | $1.21B | $1.21B – $1.21B | 1 |
| 2028 | $2.27 | $2.27 – $2.27 | $348.57M | $348.57M – $348.57M | 1 |
| 2029 | $4.66 | $4.66 – $4.66 | $713.06M | $713.06M – $713.06M | 1 |
| 2030 | $5.23 | $5.23 – $5.23 | $885.11M | $885.11M – $885.11M | 1 |
